Grading NET: Mitosis and Ki-67 conditio sine qua non? Abstract #697

Introduction: The latest WHO classification for neuroendocrine tumors (NET) defines their grade according to Ki-67 and mitotic index. However, as both parameters are markers for a different part of the cell cycle, their values might not lead to the same grade.
Aim(s): We investigated whether Ki-67 and mitotic index assesment would lead to discordant grading and which of both is most informative to predict survival.
Materials and methods: Tumors of 252 patients with NET were analyzed for mitoses and Ki-67 index. Up till now, survival data are available from 85 patients
Conference: 10th Annual ENETS Conference (2013)
Category: Pathology, grading, staging
Presenting Author: MD PhD Marie-Louise Van Velthuysen
Keywords: grade, Ki-67, mitosis, NET

To read results and conclusion, please login ...

Further abstracts you may be interested in

#696 Downgrading Due to Ki-67 Index Assessment with Image Analysis
Introduction: The latest WHO classification for neuroendocrine tumors (NET) defines their grade according to Ki-67 and mitotic index. These parameters have both shown to be prognostic.
Conference: 10th Annual ENETS Conference (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD, PhD Marie-Louise Van Velthuysen
#1881 A Gene Expression-Based Nomogram Predicts Progression Free Survival in Small Bowel NETs
Introduction: Nomograms are predictive tools that help prognosticate. A survival nomogram has been validated for small bowel NETs. A circulating NET specific 51gene signature – the NETest – has efficacy (~95%) as a predictor of progression free survival (PFS).
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Professor Mark Kidd
#129 Grade according to Ki-67 or mitotic count in gastroenteropancreatic neuroendocrine tumors
Introduction: Gastroenteropancreatic neuroendocrine tumors (NETs) are uncommon tumors with a reported incidence of 2.5-5 per 100000 population. The recent classification system of NETs proposed by the European Neuroendocrine Tumor Society (ENETS) uses both Ki-67 labelling index and mitotic index to assign grade (low, intermediate, high). It has been adopted into routine practice but there is limited data on the relationship between these indices and their effect on classification.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#979 Characteristics and Treatments of Patients with G3 Gastroenteropancreatic Neuroendocrine Tumors (G3-NET) and Neuroendocrine Carcinoma (NEC): A European Multicenter Retrospective Study
Introduction: Data on G3-NET and NEC are limited. No standard therapy following platinum-etoposide failure is established and first-line therapy in G3-NET is not codified.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Maximilian Heetfeld
#1373 Comparison of Somatostatin Analogue (SA) and Chemotherapy (CT) in Neuroendocrine Tumors (NET) Patients with Ki-67 ≤20%
Introduction: SA and CT are the most important treatment options for grade (G) 1 and G2 NET patients.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: M.D. Ersin Özaslan